ABCG2 and non-small cell lung carcinoma: Roberta et al.5 found a significant difference in drug metabolism between Gef-sensitive and -resistant cell lines, while Hegedüs et al.6 observed enhanced efflux of Gef by the drug transporter ABCG2 in Gef-resistant NSCLC cells.